TABLE OF CONTENTS
1 INTRODUCTION 71
1.1 OBJECTIVES OF THE STUDY 71
1.2 MARKET DEFINITION 71
1.3 OVERVIEW OF THE ASIA PACIFIC RADIOPHARMACEUTICALS MARKET 71
1.4 LIMITATIONS 73
1.5 MARKETS COVERED 73
2 MARKET SEGMENTATION 76
2.1 MARKETS COVERED 76
2.2 GEOGRAPHICAL SCOPE 77
2.3 YEARS CONSIDERED FOR THE STUDY 78
2.4 CURRENCY AND PRICING 78
2.5 DBMR TRIPOD DATA VALIDATION MODEL 79
2.6 MULTIVARIATE MODELLING 82
2.7 PRODUCT TYPE LIFELINE CURVE 82
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 83
2.9 DBMR MARKET POSITION GRID 84
2.10 MARKET TESTING TYPE COVERAGE GRID 86
2.11 VENDOR SHARE ANALYSIS 87
2.12 SECONDARY SOURCES 88
2.13 ASSUMPTIONS 88
3 EXECUTIVE SUMMARY 89
4 PREMIUM INSIGHTS 92
4.1 PESTEL ANALYSIS 93
4.2 PORTERS FIVE FORCES 94
4.3 PIPELINE ANALYSIS 95
4.4 PATENT ANALYSIS 96
4.5 DRUG TREATMENT RATE BY MATURED MARKETS 102
4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 103
4.7 PATIENT FLOW DIAGRAM 104
4.8 KEY PRICING STRATEGIES 104
4.9 KEY PATIENT ENROLLMENT STRATEGIES 105
5 LIST OF CYCLOTRONS 107
6 REGULATORY SCENARIO 108
6.1 ASIA-PACIFIC 108
7 MARKET OVERVIEW 109
7.1 DRIVERS 111
7.1.1 THE GROWING DEMAND FOR RADIOPHARMACEUTICALS IN DIAGNOSTICS AND CLINICAL USE 111
7.1.2 THE INCREASING NEED FOR PHARMACEUTICAL PRODUCTS ACROSS VARIED THERAPEUTIC AREAS 111
7.1.3 THE INCREASING PREVALENCE OF CHRONIC DISEASES 112
7.2 RESTRAINTS 112
7.2.1 STRINGENT REGULATIONS FOR RADIOPHARMACEUTICALS 112
7.2.2 POTENTIAL RISKS ASSOCIATED WITH RADIOPHARMACEUTICALS 112
7.3 OPPORTUNITIES 113
7.3.1 THE RISING RESEARCH AND DEVELOPMENT EXPENDITURE OF RADIOPHARMACEUTICALS 113
7.3.2 THE GROWING INCIDENCES OF COMPLEX DISEASES IN GERIATRIC POPULATION 113
7.4 CHALLENGES 114
7.4.1 HIGH COST OF DEVELOPMENT AND IMPLEMENTATION OF RADIOPHARMACEUTICALS 114
7.4.2 LACK OF TECHNICAL EXPERTISE AND HIGH COST FOR TRAINING EXISTING WORKFORCE 115
8 ASIA PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE 116
8.1 OVERVIEW 117
8.2 DIAGNOSTIC RADIOPHARMACEUTICALS 120
8.2.1 PET RADIOPHARMACEUTICALS 121
8.2.1.1 F-18 121
8.2.1.2 RU-82 121
8.2.1.3 OTHER PET ISOTOPES RADIOPHARMACEUTICALS 121
8.2.2 SPECT RADIOPHARMACEUTICALS 122
8.2.2.1 TECHNETIUM-99M 122
8.2.2.2 GALLIUM-67 122
8.2.2.3 IODINE-123 122
8.2.2.4 THALLIUM-201 122
8.2.2.5 OTHER SPECT ISOTOPES 122
8.3 THERAPEUTIC RADIOPHARMACEUTICALS 123
8.3.1 BRACHYTHERAPY ISOTOPES 124
8.3.1.1 IODINE-125 124
8.3.1.2 PALLADIUM-103 124
8.3.1.3 CESIUM-131 124
8.3.1.4 IRIDIUM-192 125
8.3.1.5 OTHER BRACHYTHERAPY ISOTOPES 125
8.3.2 BETA EMITTERS 125
8.3.2.1 IODINE-131 125
8.3.2.2 LUTHETIUM-177 125
8.3.2.3 SAMARIUM-153 125
8.3.2.4 YTTRIUM-90 125
8.3.2.5 RHENIUM-186 126
8.3.2.6 OTHER BETA EMITTERS 126
8.3.3 ALPHA EMITTERS 126
8.3.3.1 RA-223 126
8.3.3.2 OTHERS 126
9 ASIA PACIFIC RADIOPHARMACEUTICALS MARKET, BY APPLICATION 127
9.1 OVERVIEW 128
9.2 DIAGNOSTIC 131
9.2.1 PET 132
9.2.1.1 ONCOLOGY 132
9.2.1.2 CARDIOLOGY 132
9.2.1.3 NEUROLOGY 132
9.2.1.4 OTHER PET APPLICATION 132
9.2.2 SPECT 133
9.2.2.1 CARDIOLOGY 133
9.2.2.2 BONE SCANS 133
9.2.2.3 THYROID APPLICATIONS 133
9.2.2.4 PULMONARY SCANS 133
9.2.2.5 OTHER SPECT APPLICATION 133
9.3 THERAPEUTIC 134
9.3.1 THYROID INDICATIONS 135
9.3.2 BONE METASTASIS 135
9.3.3 LYMPHOMA 135
9.3.4 ENDOCRINE TUMORS 135
9.3.5 OTHER INDICATIONS 135
10 ASIA PACIFIC RADIOPHARMACEUTICALS MARKET, BY SOURCE 136
10.1 OVERVIEW 137
10.2 NUCLEAR REACTORS 140
10.3 CYCLOTRONS 141
11 ASIA PACIFIC RADIOPHARMACEUTICALS MARKET, BY END USER 142
11.1 OVERVIEW 143
11.2 HOSPITALS 146
11.3 DIAGNOSTIC CENTERS 146
11.4 CANCER RESEARCH INSTITUTES 147
11.5 AMBULATORY SURGICAL CENTERS 148
11.6 OTHERS 149
12 ASIA PACIFIC RADIOPHARMACEUTICALS MARKET, BY REGION 150
12.1 ASIA PACIFIC 151
12.1.1 CHINA 162
12.1.2 AUSTRALIA 169
12.1.3 JAPAN 176
12.1.4 SOUTH KOREA 183
12.1.5 SINGAPORE 190
12.1.6 INDIA 197
12.1.7 INDONESIA 204
12.1.8 PHILIPPINES 211
12.1.9 THAILAND 218
12.1.10 MALAYSIA 225
12.1.11 VIETNAM 232
12.1.12 REST OF ASIA-PACIFIC 239
13 ASIA PACIFIC RADIOPHARMACEUTICALS MARKET: COMPANY LANDSCAPE 240
13.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 240
14 SWOT ANALYSIS 241
15 COMPANY PROFILE 242
15.1 CARDINAL HEALTH 242
15.1.1 COMPANY SNAPSHOT 242
15.1.2 REVENUE ANALYSIS 242
15.1.3 COMPANY SHARE ANALYSIS 243
15.1.4 PRODUCT PORTFOLIO 243
15.1.5 RECENT DEVELOPMENT 244
15.2 ADVANCED ACCELERATOR APPLICATIONS, A NOVARTIS COMPANY 245
15.2.1 COMPANY SNAPSHOT 245
15.2.2 REVENUE ANALYSIS 245
15.2.3 COMPANY SHARE ANALYSIS 246
15.2.4 PRODUCT PORTFOLIO 246
15.2.5 RECENT DEVELOPMENT 246
15.3 LANTHEUS 247
15.3.1 COMPANY SNAPSHOT 247
15.3.2 REVENUE ANALYSIS 247
15.3.3 COMPANY SHARE ANALYSIS 248
15.3.4 PRODUCT PORTFOLIO 248
15.3.5 RECENT DEVELOPMENT 248
15.4 CURIUM 249
15.4.1 COMPANY SNAPSHOT 249
15.4.2 COMPANY SHARE ANALYSIS 249
15.4.3 PRODUCT PORTFOLIO 250
15.4.4 RECENT DEVELOPMENT 250
15.5 GENERAL ELECTRIC COMPANY 251
15.5.1 COMPANY SNAPSHOT 251
15.5.2 REVENUE ANALYSIS 251
15.5.3 COMPANY SHARE ANALYSIS 252
15.5.4 PRODUCT PORTFOLIO 252
15.5.5 RECENT DEVELOPMENT 252
15.6 BRACCO 253
15.6.1 COMPANY SNAPSHOT 253
15.6.2 PRODUCT PORTFOLIO 253
15.6.3 RECENT DEVELOPMENT 253
15.7 BWX TECHNOLOGIES. INC. 254
15.7.1 COMPANY SNAPSHOT 254
15.7.2 REVENUE ANALYSIS 254
15.7.3 PRODUCT PORTFOLIO 255
15.7.4 RECENT DEVELOPMENT 255
15.8 CHINA ISOTOPE & RADIATION CORPORATION 256
15.8.1 COMPANY SNAPSHOT 256
15.8.2 REVENUE ANALYSIS 256
15.8.3 PRODUCT PORTFOLIO 257
15.8.4 RECENT DEVELOPMENT 257
15.9 COQUI RADIOPHARMACEUTICALS CORP. 258
15.9.1 COMPANY SNAPSHOT 258
15.9.2 PRODUCT PORTFOLIO 258
15.9.3 RECENT DEVELOPMENT 258
15.10 ECKERT & ZIEGLER 259
15.10.1 COMPANY SNAPSHOT 259
15.10.2 REVENUE ANALYSIS 259
15.10.3 PRODUCT PORTFOLIO 260
15.10.4 RECENT DEVELOPMENT 260
15.11 ECZACIBAI-MONROL 261
15.11.1 COMPANY SNAPSHOT 261
15.11.2 PRODUCT PORTFOLIO 261
15.11.3 RECENT DEVELOPMENT 261
15.12 EVERGREEN THERAGNOSTICS, INC. 262
15.12.1 COMPANY SNAPSHOT 262
15.12.2 PRODUCT PORTFOLIO 262
15.12.3 RECENT DEVELOPMENT 262
15.13 ASIA PACIFIC MEDICAL SOLUTIONS 263
15.13.1 COMPANY SNAPSHOT 263
15.13.2 PRODUCT PORTFOLIO 263
15.13.3 RECENT DEVELOPMENT 263
15.14 IBA WORLDWIDE 264
15.14.1 COMPANY SNAPSHOT 264
15.14.2 REVENUE ANALYSIS 264
15.14.3 PRODUCT PORTFOLIO 265
15.14.4 RECENT DEVELOPMENT 265
15.15 INSTITUTE OF ISOTOPES 266
15.15.1 COMPANY SNAPSHOT 266
15.15.2 PRODUCT PORTFOLIO 266
15.15.3 RECENT DEVELOPMENT 266
15.16 ISOTOPE JSC 267
15.16.1 COMPANY SNAPSHOT 267
15.16.2 PRODUCT PORTFOLIO 267
15.16.3 RECENT DEVELOPMENT 267
15.17 JUBILANT RADIOPHARMA A JUBILANT PHARMOVA COMPANY 268
15.17.1 COMPANY SNAPSHOT 268
15.17.2 REVENUE ANALYSIS 268
15.17.3 PRODUCT PORTFOLIO 269
15.17.4 RECENT DEVELOPMENT 269
15.18 NTP 270
15.18.1 COMPANY SNAPSHOT 270
15.18.2 PRODUCT PORTFOLIO 270
15.18.3 RECENT DEVELOPMENT 270
15.19 PHARMALOGIC HOLDINGS CORP 271
15.19.1 COMPANY SNAPSHOT 271
15.19.2 PRODUCT PORTFOLIO 271
15.19.3 RECENT DEVELOPMENT 271
15.20 SHINE TECHNOLOGIES, LLC 272
15.20.1 COMPANY SNAPSHOT 272
15.20.2 PRODUCT PORTFOLIO 272
15.20.3 RECENT DEVELOPMENT 272
15.21 SIEMENS HEALTHCARE GMBH 273
15.21.1 COMPANY SNAPSHOT 273
15.21.2 REVENUE ANALYSIS 273
15.21.3 PRODUCT PORTFOLIO 274
15.21.4 RECENT DEVELOPMENT 274
16 QUESTIONNAIRE 275
17 RELATED REPORTS 278

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.